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Pairs of recombinant MVA (Modified Vaccinia Ankara) and FPV (Fowlpox Virus) expressing the same 
transgene are reasonable candidates for prime/boost regimens, because cross-reacting immune 
responses between the two vectors, both non-replicative in mammalian hosts, are very limited. The 
acceptor virus FPD-Red, a derivative of FPV, carrying a red fluorescent protein gene flanked by the 
homology regions of MVA deletion III, was constructed. The same MVA Transfer Plasmid Green, 
designed to insert transgenes into the MVA deletion III locus, can therefore be used to transfer 
transgenes into both acceptor viruses MVA-Red and FPD-Red with the described recently Red-to-
Green gene swapping method. Cells infected by either recombinant virus can be sorted differentially 
by a simple and reliable FACS-based purification protocol. The procedure is carried out in primary 
chick embryo fibroblasts grown in serum-free media and was applied to the production of three 
rMVA/rFPV pairs expressing the H5N1 avian influenza antigens M1, M2 and NP. The viral genes were 
human codon-optimized and expressed at high levels in both chick and mammalian cells. Both single-
step and multiple-step growth analyses showed no significant differences in growth due to the 
transgenes in either rMVA or rFPV derivatives. 
 
1. Introduction 
Both MVA (Modified Vaccinia Ankara) and FPV (Fowlpox Virus) poxviral strains are considered 
suitable human vaccine vectors because of the high expression of heterologous genes and the lack of 
replication in mammalian cells ( [Sutter and Moss, 1992] and [Taylor et al., 1988]). 
Fowlpox recombinants encoding tumor ( [Grosenbach et al., 2001], [Restifo et al., 1994] and [Wang et 
al., 1995]), or viral antigens ( [Feng et al., 2010], [Kent et al., 1998], [Kent et al., 2000], [Radaelli et al., 
2007] and [Steensels et al., 2009]) have been shown to elicit CD8 T cell responses in animal models. 
MVA recombinants also proved to protect against several infectious diseases and tumors in various 
animal models ( [Barouch et al., 2001], [Carson et al., 2009], [Hirsch et al., 1996], [Schneider et al., 
1998], [Sutter et al., 1994], [Weidinger et al., 2001], [Wyatt et al., 1996], [Carroll et al., 
1997] and [Drexler et al., 1998]) and have been used widely in prime-boost strategies (Amara et al., 
2002) and in clinical trials ( [Cosma et al., 2003], [Jaoko et al., 2008], [Marshall et al., 2005], 
[McConkey et al., 2003] and [Webster et al., 2006]). 
  
Despite their relatedness, cross-reacting immune responses between the two vectors are very limited ( 
[Hodge et al., 2003] and [Tsang et al., 2005]). These features make MVA and FPV ideal vectors for 
both prophylactic and therapeutic human vaccines using a prime/boost regimen to stimulate both the 
cellular and humoral arms of the immune system with high efficiency. 
A quick and reliable method to produce marker-free rMVA by swapping green and red fluorescence 
genes combined with fluorescence-activated cell sorting has been described previously (Di Lullo et al., 
2010). To facilitate the production of pairs of recombinant MVA and FPV expressing the same 
transgene, the method was extended to the production of rFPVs. To achieve this, an acceptor virus 
FPD-Red, a derivative of FPV containing an active red fluorescent protein gene flanked by the 
homology regions of MVA deletion III within the fp9.046 gene, was constructed. Consequently, the 
same Transfer Plasmid Green, designed to insert transgenes into the MVA deletion III borders by 
homology recombination (Di Lullo et al., 2010) can be used to transfer transgenes into both MVA-Red 
and FPD-Red acceptor viruses. 
 
2. Materials and methods 
2.1. Construction of recombinant virus FPD-Red 
The plasmid pIII-sP-Red (Di Lullo et al., 2010) was digested with SpeI, blunted by Klenow fragment 
and digested again with EcoRI to obtain a 1808-bp fragment containing the HcRed1.1 gene (under the 
synthetic VV promoter sP) flanked by the MVA-deletion-III homology regions. The fragment was 
inserted into the EcoRV and EcoRI sites of pBlueScript SK(-) to obtain the pSK(-)Red intermediate, 
from which the HindIII-SmaI 1836 bp fragment was derived and inserted into the HindIII and NruI sites 
within the FPV fp9.046 gene 3-β-hydroxysteroid dehydrogenase 5-delta 4 isomerase, using the 
recombinant pFP128 plasmid after excision of the gene inserted previously ( [Pozzi et al., 
2009] and [Radaelli et al., 2007]). The resulting pFP-Dual-Red Tranfer Plasmid was transfected 
(10 μg) into chick embryo fibroblasts (CEF) prepared and grown in serum-free medium (VP-SFM; 
GIBCO) and infected with FPV wild-type (FPwt) (0.05 m.o.i.) ( [Pozzi et al., 2009] and [Radaelli et al., 
2007]). The lysate derived from such infection/transfection was diluted 1/50 and used to infect CEF in 
the presence of 1 mM cytochalasin D (Di Lullo et al., 2010). Single-red cells were sorted onto CEF 
microcultures and the recombinant virus FPV-Dual-Red (FPD-Red) was cloned by two rounds of 
terminal dilution in microcultures. These cultures were monitored by whole-plate Typhoon 
fluoroimaging, which allows green or red fluorescence in microcultures to be visualized (Molecular 
Dynamics Typhoon 8600 Imager). 
 
2.2. Construction of plasmids carrying H5N1 M1, M2 and NP 
Wild-type and human codon-optimized (co) co-M1, co-M2 and co-NP genes from H5N1 Influenza 
A/Vietnam/1194/2004 were synthesized (Kotsopoulou et al., 2000) and PCR-elongated after inserting 
HindIII and BamHI restriction sites and a C-terminal sequence containing the coding sequence for the 
9 amino acid V5-tag (MDDLGSIPNPLLGLD) (Southern et al., 1991). Codon-optimized sequences are 
reported in Table S1 of Supplementary Materials. Wild-type and modified genes were cloned into the 
pTH plasmid (Hanke et al., 1998) to yield plasmids pTH-wtM1, pTH-wtM2, pTH-wtNP, pTH-coM1, 
pTH-coM2, pTH-coNP. The human codon-optimized genes were then PCR-elongated after inserting 
BamHI and AscI restriction sites and subcloned into the BamHI-AscI sites of Transfer Plasmid Green 
(TPG) (Di Lullo et al., 2010) to yield plasmids TPG-coM1, TPG-coM2 and TPG-coNP. 
 
2.3. Production of MVA and FPD recombinants 
Primary CEF were infected/transfected with MVA-Red or FPD-Red at an m.o.i. of 0.05 and TPGs 
carrying either co-M1, coM2 or co-NP transgenes (as well as the EGFP marker gene). The virus 
lysates, derived from infection/transfection and diluted 1:100, were used to infect fresh CEF in the 
presence of 1 μM cytochalasin D (Sigma–Aldrich, St. Louis, MO). Infected cells, collected 24 h p.i. by 
trypsinization, were washed and kept on ice. Green cells were either bulk- or single cell-sorted by a 
Becton Dickinson FACS Vantage SE flow cytometer (Becton Dickinson, San José, CA). EGFP 
fluorescence (excited at 488 nm) was detected using a 530/30 nm bandpass filter. HcRed1-1 
  
fluorescence (excited at 633 nm) was detected using a 660/20 nm bandpass filter. Sorted cells were 
seeded onto CEF monolayers in microplate cultures to produce virus lysates. Finally, markerless 
recombinant viruses (rMVA-M1, rMVA-M2, rMVA-NP, rFPD-M1, rFPD-M2, rFPD-NP) were cloned by 
terminal dilution and expanded in CEF by conventional methods. 
 
2.4. Virus titration 
Terminal dilution titration and cloning of rMVA and rFPD were carried out in 96-well plates, by infecting 
8 or 16 CEF microcultures with each serial 10-fold dilution of viral lysates. In order to spread viral 
infection throughout the monolayers, CEF microcultures were “scrambled” after 48 h by scraping the 
monolayers and pipetting up and down with the multichannel pipette. After an additional 48 h, the 
microcultures were monitored by fluorescence microscopy or by whole-plate fluoroimaging (Typhoon, 
GE Healthcare) to distinguish uninfected from infected cultures. A macroscopic record of viral titrations 
could also be obtained by twice freezing and thawing the microtiter plates and replica-plating 50 μl of 
the supernatants onto BHK-21 cells (seeded freshly at 2000 cells/well). For MVA-infected cultures the 
replica-plating was carried out after 4 days and for FPV-infected cultures after 6–7 days. Four days 
later, BHK-21 microcultures are fixed by acetone–methanol, washed with water and stained with 
crystal violet. MVA grows in BHK-21 and therefore only uninfected monolayers persist and are stained. 
Conversely, FPV does not grow in BHK-21 cells, but infection prevents their growth and the formation 
of a cell monolayer. Marker-free (non-fluorescent) segregants of rMVAs and rFPDs can be identified 
by comparing whole-plate fluorograms with crystal violet-stained replicas, selecting those cultures in 
which neither fluorescence nor staining occurs. 
The mean number of infecting viruses per well (m) was calculated using Poisson's distribution formula 
(m = −ln f) for the rows of microwells containing a fraction of uninfected cultures (f). 
 
2.5. Transgene expression analysis 
Western Blot. CEF, BHK-21 or HEK-293-T cells (ca. 1 × 106) infected with rMVA or rFPD at an m.o.i. 5 
(or mock-infected) were lysed with 1% NP40 in PBS and centrifuged for 5 min at 10,000 × g. The 
supernatants were incubated for 5 min in reducing sample buffer (30 mM Tris–HCl, pH 6.8, 1.5% SDS, 
10 mM beta-mercaptoethanol, 10% glycerol, 0.1 mg/mL bromophenol blue) at 100 °C. Protein 
samples were then resolved by 12% SDS–PAGE and transferred to nitrocellulose. Avian influenza 
proteins were detected using chick anti-H5N1 polyclonal antibodies (Istituto Zooprofilattico 
Sperimentale Tre Venezie, Padova, Italy), monoclonal antibodies SC-66143, SC-66143, SC-66143 
(Santa Cruz, Heidelberg, Germany), or anti-V5 monoclonal antibody V5-10 (Sigma–Aldrich) followed 
by HRP-conjugated rabbit anti-chicken Ig or anti-mouse Ig antibodies (Jackson Immunoresearch 
Laboratories Inc., West Grove, PA, USA). Western blots were developed by enhanced 
chemiluminescence (ECL; Amersham Biosciences, Milan, Italy) autoradiography. 
Foci immunostaining. Immunoperoxidase assays to detect rMVA- or rFPD-infected foci were 
performed on paraformaldehyde-fixed monolayers of CEF employing the same primary and secondary 
antibodies as above and the aminoethylcarbazole chromogenic substrate (Sigma–Aldrich). 
 
2.6. Growth parameters of recombinant viruses 
Burst size (average number of viruses produced by cells infected at 10 m.o.i.) and growth rate were 
measured by single-step and multiple-step growth analysis for all the recombinants and the 
corresponding acceptor viruses. The burst size was calculated by dividing the total number of viruses 
in CEF cultures at 48 h (for MVA derivatives), or 72 h (for FPV derivatives) by the number of cells 
present in culture at the time of infection. The growth rate was calculated as the doubling time of the 
virus titre measured on the exponential curve from 3 to 4 time points (12, 16, 20, 40 h for MVA; 19, 24, 




2.7. Real-time PCR 
A Real-time PCR assay for FPV DNA quantitation was based on the conserved region of the fp9,046 
gene carried by plasmid pFPwt. The forward and reverse primers, which amplify a 73-bp fragment and 
a probe of 18 bp complementary to an internal region 1 bp downstream of the forward primer, were 
selected using the Primer Express software (Applied Biosystem, Foster City, CA, USA) (Table S2 of 
Supplementary Materials). The thermodynamic features were predicted by the Oligo 6 software 
(Molecular Biology Insights Co, USA). The primers were synthesized by Primm (Milan, Italy), whereas 
the 3′-minor groove binder DNA probe, synthesized with the reporter dye 6-carboxy-fluorescein linked 
covalently to the 5′ end of the sequence, was prepared by Applied Biosystems (Warrington, United 
Kingdom). An extensive search in the EMBL, BLAST and GenBank databases indicated that neither 
the primers nor the probe shared significant homology with other known nucleotide sequences. The 
reaction was optimized by determining the concentrations of primers and probes and the annealing 
temperature yielding the highest intensity of reporter fluorescent signal without a reduction in 
specificity or sensitivity. CEF were seeded in 48-well plates at 40,000 cells/culture. At 24 h, FPV 
derivatives were added at an m.o.i. of 0.1. Two hours later the cells were washed and the complete 
medium restored. At various time points (18, 24, 48 and 64 h) the monolayer was washed and 
incubated with a lysis reagent described previously (Malnati et al., 2008) and proteinase K for 2 h at 
56 °C, followed by a 15 min incubation at 95 °C. A fraction of the lysate was used in TaqMan Real-
time PCR for FPV DNA quantitation. Details of the TaqMan reaction are reported in Table S2 (in 
Supplementary Materials). A standard curve was prepared with serial dilutions of known input target 




3.1. Production of an acceptor FPV suitable for gene swapping 
In order to extend to FPV the Red-to-Green gene swapping method developed recently for MVA ( [Di 
Lullo et al., 2009] and [Di Lullo et al., 2010]), and simplify the construction of rMVA/rFPV pairs for 
prime/boost vaccine regimens, the MVA deletion III flanking regions were inserted into FPV, rendering 
it suitable for homologous recombination with the same Transfer Plasmid Green used for the 
construction of rMVA. This was achieved by cloning the red fluorescent protein gene HcRed1.1 
(flanked by MVA Deletion III flanking regions) within the FPV homology regions of plasmid pFP128 ( 
[Pozzi et al., 2009] and [Radaelli et al., 2007]). 
The resulting pFP-Dual-Red (Fig. 1a) containing both sets of homology regions of FPV and MVA, 
could be used for homologous recombination. Following infection/transfection of serum-free CEF with 
the pFP-Dual-Red Transfer Plasmid and FPwt, the recombinant FP-Dual-Red (FPD-Red) virus was 
obtained by sorting red infected cells (Fig. 1b) and two rounds of cloning by terminal dilution (Fig. 1c). 
Foci of FPD-Red infected CEF are shown in Fig. 1d. 
 
3.2. Construction of recombinant MVA and FPD carrying H5N1 avian influenza genes 
The sequences of M1, M2 and NP genes of a H5N1 avian influenza virus isolate (Influenza 
A/Vietnam/1194/2004) were codon-optimized for maximal expression in mammalian cells. Wild-type 
and codon-optimized synthetic genes, containing the V5 tag at the C′ terminus, were produced and 
cloned under control of the CMV promoter into the expression plasmid pTH, which is suitable for DNA 
vaccination. Expression of the wild-type (wt) and codon-optimized (co) genes in plasmid-transfected 
293T cells was analysed by V5 Western blot analysis (Fig. 2a). The co form of the M1 gene was 
expressed at levels markedly higher than those of the wt form. An obvious increase in expression was 
also observed for the co form of the NP gene, while the M2 gene was expressed at similar levels for 
the wt and co forms. 
The codon-optimized genes were also subcloned into Transfer Plasmid Green under the control of the 
P7.5 vaccinia promoter, and the correct gene expression was checked by V5 Western blot analysis of 
cell lysates following infection/transfection of CEF with plasmid DNA and MVA-Red (not shown). MVA-
Red and FPD-Red (Fig. 2b) were then used as acceptor viruses for the construction of recombinants 
  
by the Red-to-Green gene swapping method. Following infection/transfection of CEF in serum-free 
medium, a cell lysate was prepared at 18 h p.i. and used to infect a fresh culture of CEF in the 
presence of cytochalasin D to prevent superinfection by parental (red) virus of cells infected by the 
recombinant (green) viruses. Green infected cells were sorted in batch (Fig. 2c) and grown in CEF 
cells for 2 blind passages. Cloning by terminal dilution, followed by fluorography of the whole microtiter 
plate (Fig. 2d) allowed the isolation of green clones and a few marker-less clones for each of the 
transgenes, by comparing with a replica-plate of the microcultures stained by crystal violet. 
 
3.3. Characterization of transgene expression by recombinant viruses 
Transgene expression by recombinant MVA and FPD viruses was monitored by V5 
immunofluorescence of infected CEF cells. Fig. 3a shows the expression of M1, M2 and NP avian flu 
antigens by FPD recombinant viruses. Three distinct morphological patterns for the three antigens 
were seen: M2 and NP displayed characteristic cytoplasmic membrane and nuclear localizations, 
respectively, while M1 displayed a granular/vesicular morphology. V5 Western blot analysis of all the 
six recombinants (Fig. 3b) confirmed the expected molecular weight of the recombinant proteins in 
both vector systems. The V5 immunoperoxidase morphology of infected foci in CEF monolayers is 
shown in Fig. 3c. 
 
3.4. Transgene insertion does not alter the growth parameters of recombinant viruses 
Wild-type, acceptor and recombinant viruses were analysed for their growth properties to verify 
whether the insertion/expression of the transgenes might impair virus replication. The burst size of all 
derivatives was determined by titrating the virus produced at 48 h (for MVA derivatives), or 72 h (for 
FPV/FPD derivatives) after infecting CEF at 10 m.o.i. Although the burst size of both MVA and 
FPV/FPD derivatives was unaffected by transgene insertion, it was significantly higher in MVA 
derivatives than in FPV/FPD (200 ± 31 vs. 70 ± 7; average ± se; n = 5; p = 0.0017, t test). 
The growth rate of MVA derivatives (Fig. 4a) was examined by titrating the virus produced at various 
time points after infecting CEF at 0.01 m.o.i. The exponential growth curves of all the derivatives could 
be described with a single equation (coefficient = 0.226; R2 = 0.96). The growth rate of FPV/FPD 
derivatives was analysed by virus titration and by real-time PCR. The two methods gave 
superimposable results (Fig. 4b). The exponential growth curves of all the derivatives, by both 
methods, could be described with a single equation (coefficient = 0.116; R2 = 0.97). The doubling time 
of FPV/FPD derivatives was significantly longer than that of MVA derivatives (5.98 h vs. 3.48 h; 
p < 0.0001, likelihood ratio test). 
 
4. Discussion 
The Red-to-Green gene swapping method described recently for rMVA ( [Di Lullo et al., 2009] and [Di 
Lullo et al., 2010]) consists of a flow cytometry purification protocol. Single cells infected are sorted on 
the basis of differential fluorescence, which distinguishes the parental acceptor virus carrying a red 
gene from recombinants which have swapped the red gene with a cassette containing the transgene 
and a green marker gene from the transfer plasmid. In this way, a single cell type can be used 
throughout the whole procedure. Further novelties are the introduction of a reversible inhibitor of virus 
release (such as cytochalasin D), which limits the infection to a single round, thus preventing 
superinfection by parental red viruses and the extension of the method to serum-free CEF, an 
essential step for its implementation in the field of human vaccine development. 
In order to extend to FPV the Red-to-Green gene swapping method developed for MVA and simplify 
the construction of rMVA/rFPV pairs for prime/boost vaccine regimens, homology regions derived from 
MVA (Deletion III flanking regions) were introduced into a FPV derivative, making it suitable for 
homologous recombination with the same Transfer Plasmid Green used for the construction of rMVA 
(Di Lullo et al., 2010). This was achieved by cloning the red fluorescent protein gene HcRed1.1 
(flanked by MVA Deletion III regions) within the FPV homology regions of plasmid pFPwt (Radaelli et 
al., 2007). 
  
The new method was used to construct 3 rMVA/rFPV pairs with M1, M2 and NP transgenes from 
H5N1 Influenza A/Vietnam/1194/2004, to be used in prime/boost vaccination regimens. The 
transgenes were codon-optimized to enhance expression in infected cells. This was verified 
experimentally by comparing the expression levels of wt and codon-optimized sequences in a human 
cell line (Fig. 2a). The increase in expression was particularly evident for M1 and NP, and justifies 
largely the choice of codon-optimized sequences for vaccine constructs. 
The three transgenes were expressed correctly in both MVA and FPV vectors, yielding proteins of the 
expected molecular mass. The subcellular localization of the transgenic proteins was analysed by 
immunofluorescence, which showed three distinct morphological patterns for the three antigens; M2 
and NP display characteristic cytoplasmic membrane and nuclear localizations, respectively, while M1 
(the influenza protein responsible for the budding of viruses and virus-like particles) displays a 
vesicular membrane morphology, possibly due to its ability to interact with other M1 molecules to form 
a continuous shell beneath membranes. The formation of larger vesicles was possibly due to the 
abnormally high expression of the M1 transgene. 
A possible effect of the presence and expression of transgenes on virus growth was investigated by 
analysing both the burst size and the growth rate of all MVA and FPV vectors and recombinants. No 
effect could be shown in either case. 
The titration of FPV vectors and derivatives on CEF proved to be experimentally complex compared to 
MVA derivatives, because no clear early CPE is visible and CEF monolayers of cells killed by the virus 
are not distinguishable macroscopically by crystal violet staining. A modification of the titration method 
was therefore devised; the original virus-infected CEF titration microcultures supernatants were 
transferred to BHK-21 microcultures seeded freshly with an inoculum of 500 cells/well. FPV does not 
grow in BHK-21 cells but does infect and eventually kills them. The virus concentration in the 
supernatants of infected microcultures is sufficient to sterilize the cell inoculum and prevent monolayer 
formation. 
A real-time PCR method to measure FPV DNA in infected cell cultures was also established, 
employing primers within the FPV fp9,046 gene, present in the original transfer plasmid pFPwt and 
used as a control. The method proved to be useful for evaluating growth rate. The relative increase in 
DNA copies in microcultures infected at low m.o.i. is exponential (e.g., between 18 and 64 h p.i., see 
Fig. 4b) with the same coefficient of relative increase in virus, as determined by titration using the 
described above. 
FVP derivatives grow significantly slower than MVA derivatives and achieve significantly smaller burst 
sizes. It would be interesting to evaluate if the longer survival and expression of transgenes in infected 
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Figure 1. Constructionsof the acceptor virus FPD-Red. (a) Schematic diagram of genetic constructs. 
(b) Sorting and cloning of FPD-Red. A cell lysate from infection/transfection of CEF with FPwt and 
pFP-Dual-Red Transfer Plasmid was diluted 1/50 and used to infect a fresh CEF culture in the 
presence of 1 mM cytochalasin D. Flow cytometry analysis at 18 h p.i. showed a fraction (ca. 1%) of 
red cells (Sort Window). (c) Whole-plate fluoroimaging of microtiter terminal dilution of sorted red cells 







Figure 2. Construction of recombinant MVA and FPD. (a) V5 Western blot analysis of wild-type (wt) 
and human codon-optimized (co) M1, M2 and NP genes in pTH plasmids after transfection in 293T 
cells. (b) Schematic diagram of genetic constructs. Maps of viral vector FPD-Red and Tranfer Plasmid 
Green. (c) Sorting and cloning of recombinant viruses. Cell lysates from infection/transfection of CEF 
with MVA-Red or FPD-Red and Transgene-carrying Transfer Pasmid Green DNA were diluted 1/50 
and used to infect fresh CEF cultures in the presence of 1 mM cytochalasin D. Flow cytometry 
analysis at 18 h p.i. showed a small fraction (<0.01%) of green cells (Sort Window). (d) Terminal 
dilution of sorted green cells analysed by whole-plate fluoroimaging of the original microcultures and 
by crystal violet staining of a replica plate. Most of the clones are green, but two (microtiter cultures 













Figure 3. Characterization of recombinant viruses expressing H5N1 proteins. (a) Transgene (M1, M2, 
NP) expression by MVA recombinants in infected CEF, monitored by V5 immunofluorescence (red), 
Hoechst nuclear staining (blue), merging and phase contrast. (b) V5 Western blot analysis of rMVA 
and rFPV derivatives. The arrows indicate the expected molecular masses. (c) V5 immunoperoxidase 








Figure 4. Growth analysis of recombinant virus. (a) Growth rate of MVA derivatives analysed by virus 
titration. The exponential growth curves of all the derivatives could be described with a single equation 
(coefficient = 0.226; R2 = 0.96). (b) The growth rate of FPV/FPD derivatives analysed by virus titration 
(-TIT) and by real-time PCR (-RT). The exponential growth curves of all the derivatives, by both 
methods, could be described with a single equation (coefficient = 0.116; R2 = 0.97). Dt is the doubling 
time calculated from the curves. 
 
 
 
 
  
